Literature DB >> 463982

Ovarian carcinoma: improved survival following abdominopelvic irradiation in patients with a completed pelvic operation.

A J Dembo, R S Bush, F A Beale, H A Bean, J F Pringle, J Sturgeon, J G Reid.   

Abstract

A prospective, stratified, randomized study of 190 postoperative ovarian patients with Stages IB, II, and III (asymptomatic) presentations is reported. The median time of follow-up was 52 months. Patients in whom bilateral salpingo-oophorectomy and hysterectomy (BSOH) could not be completed because of extensive pelvic tumor had a poor prognosis which did not differ for any of the therapied tested. When BSOH was completed, pelvic plus abdominopelvic irradiation (P + AB) with no diaphragmatic shielding significnatly improved patient survival rate and long-term control of occult upper abdominal disease in approximately 25% more patients than pelvic irradiation alone or followed by adjuvant daily chlorambucil therapy. The effectiveness of P + AB in BSOH-completed patients was independent of stage or tumor grade and was most clearly appreciated in patients with all gross tumor removed. Chlorambucil added to pelvic irradiation delayed the time to treatment failure without reducing the number of treatment failures.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 463982

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  15 in total

1.  Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group.

Authors:  Charles A Kunos; Michael W Sill; Thomas E Buekers; Joan L Walker; Jeanne M Schilder; S Diane Yamada; Steven E Waggoner; Mohammed Mohiuddin; Paula M Fracasso
Journal:  Gynecol Oncol       Date:  2011-02       Impact factor: 5.482

2.  Fractionated Palliative Pelvic Radiotherapy as an Effective Modality in the Management of Recurrent/Refractory Epithelial Ovarian Cancers: An Institutional Experience.

Authors:  Anshuma Bansal; Bhavana Rai; Shikhar Kumar; Vanita Suri; Sushmita Ghoshal
Journal:  J Obstet Gynaecol India       Date:  2016-07-29

Review 3.  Pursuit of optimum outcomes in ovarian cancer: methodological approaches to therapy.

Authors:  D D Gibbs; M E Gore
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Postoperative abdominopelvic irradiation in patients with epithelial cancer of ovary. The Princess Margaret Hospital Experience.

Authors:  A J Dembo
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

Review 5.  Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.

Authors:  Brett A Winter-Roach; Henry C Kitchener; Theresa A Lawrie
Journal:  Cochrane Database Syst Rev       Date:  2012-03-14

6.  Whole abdomen radiation therapy in ovarian cancers: a comparison between fixed beam and volumetric arc based intensity modulation.

Authors:  Umesh Mahantshetty; Swamidas Jamema; Reena Engineer; Deepak Deshpande; Rajiv Sarin; Antonella Fogliata; Giorgia Nicolini; Alessandro Clivio; Eugenio Vanetti; Shyamkishore Shrivastava; Luca Cozzi
Journal:  Radiat Oncol       Date:  2010-11-15       Impact factor: 3.481

Review 7.  Then and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective.

Authors:  Madalyn G Neuwirth; H Richard Alexander; Giorgos C Karakousis
Journal:  J Gastrointest Oncol       Date:  2016-02

8.  Sequential cisplatin/cyclophosphamide chemotherapy and abdominopelvic radiotherapy in the management of advanced ovarian cancer.

Authors:  J A Green; H M Warenius; R D Errington; S Myint; G Spearing; A J Slater
Journal:  Br J Cancer       Date:  1988-11       Impact factor: 7.640

Review 9.  Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.

Authors:  Theresa A Lawrie; Brett A Winter-Roach; Pauline Heus; Henry C Kitchener
Journal:  Cochrane Database Syst Rev       Date:  2015-12-17

10.  The treatment of intraperitoneal malignant disease with monoclonal antibody guided 131I radiotherapy.

Authors:  B Ward; S Mather; J Shepherd; M Crowther; L Hawkins; K Britton; M L Slevin
Journal:  Br J Cancer       Date:  1988-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.